ACHV
NASDAQ · Biotechnology
Achieve Life Sciences Inc
$4.77
-0.52 (-9.83%)
Open$5.41
Previous Close$5.29
Day High$5.41
Day Low$4.67
52W High$6.15
52W Low$2.00
Volume—
Avg Volume1.31M
Market Cap551.79M
P/E Ratio—
EPS$-1.29
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+568.6% upside
Current
$4.77
$4.77
Target
$31.89
$31.89
$22.93
$31.89 avg
$41.27
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 52.78B | 95.39B | 656.40M |
| Net Income | -130,750,807 | -212,679,787 | 10.36M |
| Profit Margin | -397.8% | -377.9% | 1.6% |
| EBITDA | -131,397,521 | -225,605,720 | 18.53M |
| Free Cash Flow | — | — | 6.70M |
| Rev Growth | -44.7% | -44.7% | +1.9% |
| Debt/Equity | 0.69 | 0.69 | 0.12 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $213.76 | +2.08% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $330.33 | -0.13% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $130.28 | -0.17% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $429.32 | -1.15% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $641.69 | +1.81% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $293.86 | -0.15% | 66.6 | 38.43B |